cjc-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
In 1986, Australians Kevin Barlow and Brian Chambers became the first Westerners executed under Malaysia's mandatory death penalty for drug trafficking, despite last-minute clemency appeals from Australia and the United Kingdom. Mahathir defended the decision, emphasizing that Malaysia's strict anti-drug laws applied equally to all, regardless of nationality or background. In Mahathir's early years as prime minister, Malaysia experienced a resurgence of Islam and conservatism among Malays. PAS, which had joined UMNO in government in the 1970s, responded to the resurgence by taking an increasingly strident Islamist stand under the leadership of Yusof Rawa. Mahathir tried to appeal to religious voters by establishing Islamic institutions such as the International Islamic University of Malaysia which could promote Islamic education under government oversight. He managed to draw Anwar Ibrahim, the leader of the Malaysian Islamic Youth Movement (ABIM), into the ranks of UMNO. In some cases, Mahathir's government employed repression against more extreme exponents of Islamism. Ibrahim Libya, a popular Islamist leader, was killed in a police shoot-out in 1985. Al-Arqam, a religious sect, was banned, and its leader, Ashaari Mohammad, was arrested under the Internal Security Act. Mahathir comprehensively defeated PAS at the polls in 1986, winning 83 seats of the 84 seats it contested, leaving PAS with just one Member of Parliament (MP).
== Career == After college, Shaw decided to move to Los Angeles, but discovered she was pregnant. Much of her struggles to work as an actor while being a single mother are the loose inspiration for SMILF. A role in the 2014 ABC ensemble series Mixology was a breakout role, providing Shaw with her first sense of financial stability since giving birth to her son. In 2009, Shaw first received recognition in the completely improvised Katie Aselton-directed film The Freebie and then as the oddball drunken cheerleader Mary Jo Cacciatore in the 2010 sitcom Blue Mountain State. In 2013, Shaw appeared in the HBO's TV series starring Stephen Merchant called Hello Ladies. She had roles in the 2013 independent film The Pretty One, which starred Zoe Kazan and Jake Johnson, and the 2014 romantic comedy film Someone Marry Barry. Also in 2014, Shaw appeared in another independent feature, the drama Lullaby, which starred Garrett Hedlund and Amy Adams. In 2015, Shaw had a recurring role on the first season of the television series Mr. Robot as Shayla Nico, the drug dealing love interest of Elliot Alderson, for seven episodes. In 2015, she appeared in the ABC Family pilot Tough Cookie as well as on the 2015 Fox TV series Mulaney. In 2016, Shaw reprised her role of Mary Jo Cacciatore from the 2010 series in the movie Blue Mountain State: The Rise of Thadland. Also in 2016, Shaw appeared in the Netflix series Flaked. She was a series regular on the 2016 TV series Good Girls Revolt.
A separate co-op campaign is also available for up to four players, following a parallel plot where the players control a group of police officers that also get trapped in the nightmare world while investigating Simon. Additionally, there is also a co-op survival mode, where players fight several waves of enemies for a set period of time. Some days before Cry of Fear's anniversary, Valve released a Half-Life update for Linux compatibility, making changes in the folders and engine. This update made several Half-Life mods, including Cry of Fear, incompatible with the base game. Team Psykskallar decided that, since no more could be done for the mod itself, they would finish a standalone version. Confusion due to Valve regarding Cry of Fear's status as freeware caused the game to be delayed until April 25, 2013.
=== Intravenous injection === The administration of estradiol by intravenous injection has been studied. It achieves extremely high peak levels of estradiol but has a very short duration. Kuhnz et al. (1993) reported that a single intravenous injection of 0.3 mg estradiol resulted in peak estradiol concentrations of 8,321 pg/mL at 5 minutes post-injection. Estradiol levels decreased to 1,628 pg/mL after 30 minutes, to 778 pg/mL after 1 hour, and to 23 pg/mL after 6 hours. Leyendecker et al. (1975) reported that a single intravenous injection of 20 mg estradiol resulted in estradiol levels of 2,950 pg/mL at 12 hours after the injection (earlier time points were not measured). Following this, estradiol levels decreased to around 400 pg/mL by 24 hours post-injection and reached near-baseline levels of 45 pg/mL after 48 hours. The ratio of estradiol to estrone is very high initially (e.g., around 10:1 at peak) but becomes smaller as estradiol levels decline. The distribution half-life of intravenous estradiol is about 6 minutes and the terminal half-life of intravenous estradiol is about 0.5 to 2 hours. The peak estradiol levels are far higher and the duration far shorter when estradiol is given by intravenous injection than when estradiol esters are administered by intramuscular or subcutaneous injection. The administration of estradiol valerate by intravenous injection has been studied as well. It has been found to be very rapidly cleaved into estradiol in the blood. The metabolism of estradiol valerate does not differ with intravenous versus intramuscular injection.
Sources: en.wikipedia.org
=== Non-physician use === In the United States, it has become more common for non-physician roles to wear white coats in clinical settings, with positions such as mid-level practitioners, nurse administrators, clinical social workers, and other healthcare fields donning the coats. Some nursing schools even provide white coat ceremonies to new nursing students.
=== Interactions between biomolecules === Coimmunoprecipitation Electrophoretic mobility shift assay Southwestern blotting Isothermal titration calorimetry Fluorescence anisotropy Microscale thermophoresis
=== Statins === Statin medications are widely prescribed for treating atherosclerosis. They have shown benefit in reducing cardiovascular disease and mortality in those with high cholesterol with few side effects. Secondary prevention therapy, which includes high-intensity statins and aspirin, is recommended by multi-society guidelines for all patients with a history of ASCVD (atherosclerotic cardiovascular disease) to prevent the recurrence of coronary artery disease, ischemic stroke, or peripheral arterial disease. However, prescription of and adherence to these guideline-concordant therapies is lacking, particularly among young patients and women. Statins work by inhibiting HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase, a hepatic rate-limiting enzyme in cholesterol's biochemical production pathway. Inhibiting this rate-limiting enzyme reduces the body's ability to produce cholesterol endogenously, thereby reducing LDL-cholesterol levels in the blood. This reduced endogenous cholesterol production triggers the body to pull cholesterol from other cellular sources, enhancing serum HDL-cholesterol. These data are primarily in middle-aged men; the conclusions are less clear for women or for people over the age of 70.
and Canada that contain aspartame must be labeled: "Phenylketonurics: Contains phenylalanine." In the UK, foods containing aspartame must carry ingredient panels that refer to the presence of "aspartame or E951" and they must be labeled with a warning "Contains a source of phenylalanine." In Brazil, the label "Contém Fenilalanina" (Portuguese for "Contains Phenylalanine") is mandatory in products which contain it. These warnings are placed to help individuals avoid such foods.
== Terminology == The name "antivenin" comes from the French word venin, meaning venom, which in turn was derived from Latin venenum, meaning poison. Historically, the term antivenin was predominant around the world, its first published use being in 1895. In 1981, the World Health Organization decided that the preferred terminology in the English language would be venom and antivenom rather than venin and antivenin or venen and antivenene.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.